Clinical Trial Update: Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria [Phase 2]

View source ↗

Summary

Phase 2 long-term safety update for BCX9930 in adults with paroxysmal nocturnal hemoglobinuria; the study is terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• BCX9930 (Factor D inhibitor)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Status: TERMINATED | Results posted: 2025-10-24